Validation of a Novel Allergy‐Specific Domain for the 22‐Item Sino‐Nasal Outcomes Test
Otolaryngology–Head and Neck Surgery · 2024
DOI: 10.1002/ohn.605 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2024. Verfasst von Anne Y Feng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Rutgers University, Newark, New Jersey. Hauptthemen laut MEDLINE: Rhinitis, Sinusitis, Rhinitis, Allergic, Nasal Obstruction. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Objectives
To develop and assess the validity of a novel allergy‐specific domain for the 22‐item sino‐nasal outcomes test (SNOT‐22), to provide a new tool that efficiently quantifies the impact of allergic rhinitis (AR) concurrent with chronic rhinosinusitis. Study Design Prospective validation study .
Setting
Tertiary care hospital and community‐based clinic .
Methods
Proposed items were developed based on clinician and patient input, and further assessed via factor analysis and for internal consistency ( n = 1987). Items were then additionally assessed for convergent and discriminant validity ( n = 415), applying data from concurrent completions of the Nasal Obstruction and Septoplasty Effectiveness Scale (NOSE), Mini‐Rhinoconjunctivitis Quality‐of‐Life Questionnaire (MiniRQLQ), and validated global health assessments. Assessments of intra‐rater reliability, responsiveness to change, and qualitative input were also performed.
Results
Factor analysis demonstrated that proposed allergy items mapped to a single domain. Items were internally consistent (Cronbach α : 0.80 within domain, 0.91 within all SNOT). In assessments of convergent validity, domain scores were associated with MiniRQLQ (Spearman's ρ : 0.46, 95% confidence interval [CI]: 0.30‐0.59) and NOSE scores (0.36, 95% CI: 0.27‐0.44). The novel items also discriminated among clinical states: a 1‐point increase in domain score was associated with an 8.32 (95% CI: 5.43‐12.75) increase in the odds of prompting a visit for allergy‐related symptoms and a 1.52 (95% CI: 1.13‐2.05) increase in the odds of positive allergy testing. Intra‐rater reliability was substantial (Cohen's κ : 0.8, 95% CI: 0.8‐0.9), and responsiveness to change was demonstrated (mean difference: −0.6, 95% CI: −0.8 to −0.4).
Conclusions
This novel domain is a valid, efficient measure of AR alongside rhinosinusitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Rutgers University, Newark, New Jersey.
- Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Otolaryngology-Head and Neck Surgery, Washington University, St. Louis, Missouri, USA.
- Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Zitieren
APA
Feng, A. Y., Kim, M., Prince, A. A., Corrales, C. E., Li, A., Willard, E., Forrester, C. A., Piccirillo, J., & Shin, J. J. (2024). Validation of a Novel Allergy‐Specific Domain for the 22‐Item Sino‐Nasal Outcomes Test. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.605
Vancouver
Feng AY, Kim M, Prince AA, Corrales CE, Li A, Willard E, et al. Validation of a Novel Allergy‐Specific Domain for the 22‐Item Sino‐Nasal Outcomes Test. Otolaryngology–Head and Neck Surgery. 2024. doi:10.1002/ohn.605
BibTeX
@article{Feng2024,
author = {Feng, Anne Y and Kim, Minjee and Prince, Anthony A and Corrales, Carleton E and Li, Anne and Willard, Elizabeth and Forrester, Carly A and Piccirillo, Jay and Shin, Jennifer J},
title = {Validation of a Novel Allergy‐Specific Domain for the 22‐Item Sino‐Nasal Outcomes Test},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2024},
doi = {10.1002/ohn.605}
}
EUVIMED